» Articles » PMID: 30496290

A Natural Antisense LncRNA Controls Breast Cancer Progression by Promoting Tumor Suppressor Gene MRNA Stability

Abstract

The human genome encodes thousands of long noncoding RNA (lncRNA) genes; the function of majority of them is poorly understood. Aberrant expression of a significant number of lncRNAs is observed in various diseases, including cancer. To gain insights into the role of lncRNAs in breast cancer progression, we performed genome-wide transcriptome analyses in an isogenic, triple negative breast cancer (TNBC/basal-like) progression cell lines using a 3D cell culture model. We identified significantly altered expression of 1853 lncRNAs, including ~500 natural antisense transcript (NATs) lncRNAs. A significant number of breast cancer-deregulated NATs displayed co-regulated expression with oncogenic and tumor suppressor protein-coding genes in cis. Further studies on one such NAT, PDCD4-AS1 lncRNA reveal that it positively regulates the expression and activity of the tumor suppressor PDCD4 in mammary epithelial cells. Both PDCD4-AS1 and PDCD4 show reduced expression in TNBC cell lines and in patients, and depletion of PDCD4-AS1 compromised the cellular levels and activity of PDCD4. Further, tumorigenic properties of PDCD4-AS1-depleted TNBC cells were rescued by exogenous expression of PDCD4, implying that PDCD4-AS1 acts upstream of PDCD4. Mechanistically, PDCD4-AS1 stabilizes PDCD4 RNA by forming RNA duplex and controls the interaction between PDCD4 RNA and RNA decay promoting factors such as HuR. Our studies demonstrate crucial roles played by NAT lncRNAs in regulating post-transcriptional gene expression of key oncogenic or tumor suppressor genes, thereby contributing to TNBC progression.

Citing Articles

The impact of ferroptosis and ferroptosis-related non-coding RNAs on breast cancer progression.

Liu W, Jiang C, Ma Y, Wang W, Peng J, Ma W Front Cell Dev Biol. 2025; 12:1506492.

PMID: 39763590 PMC: 11701165. DOI: 10.3389/fcell.2024.1506492.


Radiotherapy and breast cancer: finally, an lncRNA perspective on radiosensitivity and radioresistance.

Yazarlou F, Martinez I, Lipovich L Front Oncol. 2024; 14:1437542.

PMID: 39346726 PMC: 11427263. DOI: 10.3389/fonc.2024.1437542.


Beyond the Genome: Deciphering the Role of MALAT1 in Breast Cancer Progression.

Hussain M, Agrawal M, Shaikh N, Saraswat N, Bahl G, Bhat M Curr Genomics. 2024; 25(5):343-357.

PMID: 39323624 PMC: 11420562. DOI: 10.2174/0113892029305656240503045154.


Biological and clinical relevance of correlated expression levels of coding and long noncoding RNAs in HPV16 positive cervical cancers.

Ghosh A, Sinha A, Ghosh A, Roy S, Mallick S, Kumar V Hum Genomics. 2024; 18(1):91.

PMID: 39210444 PMC: 11360852. DOI: 10.1186/s40246-024-00660-2.


MANCR lncRNA Modulates Cell-Cycle Progression and Metastasis by Cis-Regulation of Nuclear .

Singh D, Cong Z, Song Y, Liu M, Chaudhary R, Liu D Mol Cell Biol. 2024; 44(9):372-390.

PMID: 39133105 PMC: 11376416. DOI: 10.1080/10985549.2024.2383773.


References
1.
Mattick J, Rinn J . Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol. 2015; 22(1):5-7. DOI: 10.1038/nsmb.2942. View

2.
Kotta-Loizou I, Vasilopoulos S, Coutts R, Theocharis S . Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment. Neoplasia. 2016; 18(11):674-688. PMC: 5071540. DOI: 10.1016/j.neo.2016.09.002. View

3.
Yoshigai E, Hara T, Inaba H, Hashimoto I, Tanaka Y, Kaibori M . Interleukin-1β induces tumor necrosis factor-α secretion from rat hepatocytes. Hepatol Res. 2013; 44(5):571-83. DOI: 10.1111/hepr.12157. View

4.
Anantharaman A, Gholamalamdari O, Khan A, Yoon J, Jantsch M, Hartner J . RNA-editing enzymes ADAR1 and ADAR2 coordinately regulate the editing and expression of Ctn RNA. FEBS Lett. 2017; 591(18):2890-2904. PMC: 5612911. DOI: 10.1002/1873-3468.12795. View

5.
Kadota M, Sato M, Duncan B, Ooshima A, Yang H, Diaz-Meyer N . Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res. 2009; 69(18):7357-65. PMC: 2745517. DOI: 10.1158/0008-5472.CAN-09-0064. View